Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

A recent study found that the triple-layer sign (TLS) obtained on optical coherence tomography has high sensitivity and ...

Reticular pseudodrusen and subretinal hyperreflective material are among the OCT findings that may predict macular atrophy in ...

"Our approach achieved remarkably high levels of gene correction," said Dr. György. "We observed average editing rates of 75% ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...